Skip to main content
. 2023 Jun 27;40(8):2013–2020. doi: 10.1007/s10815-023-02870-4

Table 2.

Patients’ characteristics stratified by sperm retrieval outcome

Median (IQR) p value Mean (SD) p value
mTESE outcome mTESE outcome
Successful (n = 11) Unsuccessful (n = 12) Successful (n = 11) Unsuccessful (n = 12)
Male age at TESE, years 38 (34–40.5) 40 (33–41) .740 38.0 (5.7) 36.7 (5.7) .740
Male FSH, mIU/ml 22.3 (17.1–24.9) 19.6 (15–24.1) .651 22.4 (14.7) 19.6 (8.2) .651
Male LH, mIU/ml 7.2 (6.5–10.9) 7.6 (5.8–11.1) .928 8.7 (4.6) 8.9 (5.3) .928
Male testosterone, ng/ml 4.4 (3.3–4.9) 2.2 (1.8–3.0) .079 5.1 (4.5) 3.1 (2.5) .079
Male prolactin, ng/ml 10.6 (8.9–15.4) 8.5 (5.2–10.3) .059 10.6 (4.7) 9.6 (5.1) .059
Male estradiol, pg/ml 19.5 (19.0–29.6) 18.7 (16.8–21.5) .316 24.9 (14.7) 25.2 (22.6) .316
Time from C/T to mTESE, years 7 (5–18.5) 10 (4–19) .928 10.8 (8.5) 12.7 (12.7) .928
Testis volume, ml 13 (10–16.5) 11 (8–17) .525 13.4 (4.7) 12.8 (7.3) .525
Alkylating agents exposure, number 1 (9%) 8 (67%) .009 1 (9%) 8 (67%) .009
CED dose, mg/m2 0 (0–0) 3049.8 (0–8470.6) .012 249.0 (825.8) 8523.2 (14,891.5) .012
Platinum-based agents exposure, number 8 (73%) 7 (58%) .667 8 (73%) 7 (58%) .667
Accumulative cisplatin dose, mg/m2 294.1 (0–347.5) 45.3 (0–336.2) .928 218.2 (228.6) 181.5 (228.6) .928